Inhibition of PARP1‐dependent end‐joining contributes to Olaparib‐mediated radiosensitization in tumor cells

Molecular Oncology - Tập 8 Số 8 - Trang 1616-1625 - 2014
Annika Kötter1, Kerstin Cornils2, Kerstin Borgmann1, Jochen Dahm‐Daphi1, Jens Peter Klußmann3, Ekkehard Dikomey1, Waël Mansour1,4
1Laboratory of Radiobiology & Experimental Radiooncology, University Medical Center Hamburg–Eppendorf, Hamburg 20246, Germany
2Institute of Bone Marrow Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.
3Department of Radiotherapy & Radiooncology, University Medical Center Hamburg, Eppendorf, Hamburg 20246, Germany
4Tumor Biology Department, National Cancer Institute, Cairo University, Egypt

Tóm tắt

Poly‐ADP‐ribose‐polymerase inhibitors (PARPi) are considered to be optimal tools for specifically enhancing radiosensitivity. This effect has been shown to be replication‐dependent and more profound in HR‐deficient tumors. Here, we present a new mode of PARPi‐mediated radiosensitization which was observed in four out of six HR‐proficient tumor cell lines (responders) investigated, but not in normal cells. This effect is replication‐independent, as the radiosensitization remained unaffected following the inhibition of replication using aphidicolin. We showed that responders are radiosensitized by Olaparib because their DSB‐repair is switched to PARP1‐dependent end‐joining (PARP1‐EJ), as evident by (i) the significant increase in the number of residual γH2AX foci following irradiation with 3Gy and treatment with Olaparib, (ii) the enhanced enrichment of PARP1 at the chromatin after 3Gy and (iii) the inhibition of end‐joining activity measured by a specific reporter substrate upon Olaparib treatment. This is the first study which directly demonstrates the switch to PARP1‐EJ in tumor cells and its contribution to the response to Olaparib as a radiosensitizer, findings which could widen the scope of application of PARPi in tumor therapy.

Từ khóa


Tài liệu tham khảo

10.1074/jbc.M404524200

10.1038/sj.onc.1205200

10.1093/nar/gkh842

10.1038/ncb1599

10.1042/BST0320959

10.1023/A:1021692801278

10.1016/j.ijrobp.2008.07.031

10.1038/nature03445

10.1038/nrd4147

10.1126/science.278.5340.1064

10.1016/j.dnarep.2007.02.006

Huhn D., 2013, Targeting DNA double-strand break signalling and repair: recent advances in cancer therapy, Swiss Med. Wkly., 143, w13837

10.1016/j.radonc.2009.06.024

10.1007/s11103-013-0065-9

10.1038/nrc1691

10.1016/j.radonc.2008.10.019

10.1016/0360-3016(88)90403-8

10.1074/jbc.M110.140350

10.1111/j.1462-5822.2007.00901.x

Li Z., 2007, Insertional mutagenesis by replication-deficient retroviral vectors encoding the large T oncogene, Ann. N. Y. Acad. Sci.

10.1038/nm.3369

10.1158/1535-7163.MCT-09-1027

10.1093/nar/gkn347

10.1093/nar/gkq387

10.1016/j.dnarep.2013.10.005

10.1038/sj.onc.1204571

10.1016/j.cell.2007.10.005

10.1056/NEJMoa1011418

Ossovskaya V., 2010, Upregulation of poly (ADP-ribose) polymerase-1 (PARP1) in triple-negative breast Cancer and other primary human tumor types, Genes & Cancer, 10

10.1016/j.ctrv.2010.03.003

10.1038/sj.onc.1204148

10.1038/nrclinonc.2010.172

10.1158/1535-7163.MCT-11-0278

Shin K.H., 2006, Abnormal DNA end-joining activity in human head and neck cancer, Int. J. Mol. Med., 17, 917

10.1101/sqb.2005.70.012

10.1038/35088000

10.1093/nar/gkg728

10.1093/nar/gkl840

10.1016/j.molcel.2007.12.029

Thông tin
Thông tin xuất bản

Molecular Oncology

Tập 8 Số 8

1616-1625

Thông tin tác giả